PXD029233

PXD029233 is an original dataset announced via ProteomeXchange.

Title	MDR1 Drug Efflux Pump Promotes Acquired and Intrinsic Resistance to Protein Degraders in Cancer Cells
Description	PROTACs (Proteolysis-Targeting Chimeras) represent a revolutionary new class of drugs that selectively degrade proteins of interest from cells. PROTACs targeting oncogenes are avidly being explored for cancer therapies, with several currently in clinical trials. Drug resistance represents a significant challenge in cancer therapies, and the mechanism by which cancer cells acquire resistance to protein degraders remains poorly understood. Here, we applied proteomics approaches to elucidate resistance mechanisms to protein degrader therapies in cancer cells. Our studies revealed acquired resistance to degrader therapies in cancer cells can be mediated by upregulation of the ATP-dependent drug efflux pump MDR1. Degrader-resistant cells could be re-sensitized to PROTACs through co-administering MDR1 inhibitors. Notably, MDR1 is frequently overexpressed in cancer, and cancer cell lines overexpressing MDR1 exhibited intrinsic resistance to protein degraders, requiring co-treatment with MDR1 inhibitors to achieve protein degradation and therapeutic response. Notably, co-treatment of MDR1-overexpressing K-ras mutant colorectal cancer cells with MEK1/2 or K-ras degraders and the dual ErbB receptor/MDR1 inhibitor lapatinib exhibited potent drug synergy due to simultaneous blockade of MDR1 activity and ErbB receptor-driven resistance. Together, our findings showed overexpression of MDR1 can promote both intrinsic and acquired resistance to protein degraders in cancer cells and that concurrent blockade of MDR1 will likely be required to achieve durable protein degradation and therapeutic response.
HostingRepository	PRIDE
AnnounceDate	2023-11-14
AnnouncementXML	Submission_2023-11-14_08:26:37.646.xml
DigitalObjectIdentifier
ReviewLevel	Peer-reviewed dataset
DatasetOrigin	Original dataset
RepositorySupport	Unsupported dataset by repository
PrimarySubmitter	James Duncan
SpeciesList	scientific name: Homo sapiens (Human); NCBI TaxID: 9606;
ModificationList	iodoacetamide derivatized residue
Instrument	Q Exactive; Q Exactive Plus

Revision	Datetime	Status	ChangeLog Entry
0	2021-10-20 03:05:35	ID requested
1	2022-10-06 12:39:43	announced
⏵ 2	2023-11-14 08:26:42	announced	2023-11-14: Updated project metadata.

Kurimchak AM, Herrera-Mont, á, vez C, Montserrat-Sangr, à S, Araiza-Olivera D, Hu J, Neumann-Domer R, Kuruvilla M, Bellacosa A, Testa JR, Jin J, Duncan JS, The drug efflux pump MDR1 promotes intrinsic and acquired resistance to PROTACs in cancer cells. Sci Signal, 15(749):eabn2707(2022) [pubmed]

submitter keyword: MDR1, Degrader, Cancer, PROTAC, Drug Resistance, ABCB1

James Duncan
contact affiliation	Cancer Biology, Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
contact email	james.s.duncan@fccc.edu
lab head
James Duncan
contact affiliation	Fox Chase Cancer Center
contact email	james.s.duncan@fccc.edu
dataset submitter

Dataset FTP location NOTE: Most web browsers have now discontinued native support for FTP access within the browser window. But you can usually install another FTP app (we recommend FileZilla) and configure your browser to launch the external application when you click on this FTP link. Or otherwise, launch an app that supports FTP (like FileZilla) and use this address: ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2022/10/PXD029233

PRIDE project URI

• PRIDE
  1. PXD029233
     1. Label: PRIDE project
     2. Name: MDR1 Drug Efflux Pump Promotes Acquired and Intrinsic Resistance to Protein Degraders in Cancer Cells